Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab ... Trial groups (ENGOT), and NRG Oncology-Japan. Patients were of a median age of 51 years old ...

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and ...

Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug ...

Beyond Libtayo, Regeneron's oncology pipeline includes several promising programs that could add significant revenue the coming years. Fianlimab is the company’s LAG3 antibody, which has ...

Regeneron employee works on a pharmaceutical drug. Photo courtesy of Regeneron Pharmaceuticals HOLLY SPRINGS, N.C. – FujiFilm Diosynth Biotechnologies today announced ...

The agreement is valued at over $3 billion and increases U.S. manufacturing capacity to help ensure patient access to ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals ... the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara. More Top Stocks Daily: Go behind ...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

Dupixent is the first new targeted therapy for CSU in a decade and is already approved in several countries, including Japan and Brazil ... Scientific Officer at Regeneron, and a principal ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Regeneron Pharmaceuticals ... injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma ...